Highlights Telo Genomics Corp.

Equities

TELO

CA87975M2085

Market Closed - Toronto S.E. Other stock markets 03:00:28 2024-05-02 pm EDT			5-day change	1st Jan Change
0.15 ^CAD	0.00%		-11.76%	-25.00%

Apr. 10	Telo Genomics Receives Accreditation from College of American Pathologists	MT
Apr. 10	Telo Genomics Corp. Receives Accreditation from College of American Pathologists	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Telo Genomics Receives Accreditation from College of American Pathologists	Apr. 10	MT
Telo Genomics Corp. Receives Accreditation from College of American Pathologists	Apr. 10	CI
Telo Genomics Corp. Announces Patient Recruitment for Its Minimal Respiratory Disease Clinical Trial Has Been Initiated, with Several Patient Samples Received and Processed to Date	Apr. 02	CI
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 27	CI
Telo Genomics Corp. Initiates MRD Clinical Trial for Multiple Myeloma Patients	Feb. 13	CI
Telo Genomics Corp. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 22	CI
Telo Genomics Corp. Announces the American Society of Hematology Accepts the Results of Teloview-Smm Technical Repeatability Validation for Presentation At Their Annual Meeting in December 10, 2023	Nov. 01	CI
Telo Genomics Corp. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-30	CI
Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved	23-10-17	CI
Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting	23-10-12	CI
Telo Genomics Corp. Reports Substantial Progress Toward Clinical Launch of Teloview-SMM	23-08-28	CI
Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023	23-06-12	CI
Telo Genomics Corp. Presents Superior Results of Its Smoldering Multiple Myeloma Studies At Asco 2023	23-06-05	CI
Telo Genomics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-18	CI
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress	23-05-04	CI
Telo Genomics Corp. Advances to Final Stage of ISO Certification	23-03-15	CI
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-28	CI
Telo Genomics Corp. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-17	CI
Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma	22-11-09	MT
Telo Genomics Corp. Launches A Minimal Residual Disease Clinical Trial in Multiple Myeloma	22-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Telo Genomics Corp.

Equities

TELO

CA87975M2085

Highlights

Filters